Josh Cohen, Justin Klee
July 1, 2020 08:00 AM EDTUpdated July 2, 03:10 AM
Financing

Armed with pos­i­tive ALS da­ta, Amy­lyx scores $30M in fresh fund­ing to com­plete Alzheimer's PhII

Amber Tong

Four years af­ter an­nounc­ing them­selves to the biotech world with a new idea for drug­ging neu­rode­gen­er­a­tion, back­ing by the late Hen­ri Ter­meer and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times